Korean JLK Inspection launches AI-powered imaging diag system
Korean JLK Inspection said yesterday that it launched its AIHub artificial intelligence-powered medical image diagnostics platform. The newly launched AIHub system is designed to analyze images from a number of different imaging modalities, including magnetic resonance imaging, computed tomography, X-ray and mammography, the Seoul-based company said. JLK Inspection claims the system can detect and monitor for more than 30 medical conditions in 14 regions of the body. The company added that the system is focused on brain diseases and conditions including ischemic stroke, hemorrhagic stroke, brain aneurysm and Alzheimer’s disease, as well as lung cancer, prostate cancer, breast cancer, coronary artery disease and other digital pathology. “We are excited to show how we are able to assist users with quantitative analysis of their medical images at their own convenience. The ability to provide optimal diagnosis support based on deep learning technologies, unique algorithms and imaging procession techniques will be a great benefit to all patients, whether suffering from minor or major ailments,” CEO Won Tae Kim said in a press release. JLK Inspection said that it has raised over $17 million so far in venture capital funding, and that it is planning an initial public offering in Korea some time during the second half of next year. The post Korean JLK Inspection launches AI-powered imaging diag system appeared first on MassDevice.
Publication date: Available online 11 August 2020Source: Journal of Oral BiosciencesAuthor(s): Sho Akashi, Takashi Nishida, Tomomi Mizukawa, Kazumi Kawata, Masaharu Takigawa, Seiji Iida, Satoshi Kubota
Publication date: Available online 11 August 2020Source: Carbohydrate PolymersAuthor(s): Sevil Vaghefi Moghaddam, Fatemeh Abedi, Effat Alizadeh, Behzad Baradaran, Nasim Annabi, Abolfazl Akbarzadeh, Soodabeh Davaran
Publication date: Available online 11 August 2020Source: Carbohydrate PolymersAuthor(s): Jingwen Luo, Tao Gong, Lixin Ma
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Silvia Malavasi, Alessandro Bevilacqua, Giampaolo Gavelli, Domenico Barone
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Hong Chen, Xianpan Pan, Xuesong Lu, Qinlan Xie
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Stephanos Leandrou, Demetris Lamnisos, Panicos A. Kyriacou, Stephanie Constanti, Constantinos S. Pattichis, for the Alzheimer's Disease Neuroimaging Initiative
Publication date: July 2020Source: Biomedical and Environmental Sciences, Volume 33, Issue 7Author(s): Fei Ran WEI, Li Lin XIONG, Wei LI, Xue Rong WANG, Xin HONG, Bao An CHEN
CONCLUSION: Self-reported health service usage after mammographic screening is higher in women who have been notified they have dense breasts. SO WHAT?: There is growing pressure for screening programs in Australia and internationally to routinely measure and report breast density to participants. Results from this study can inform screening programs of the likely impact of breast density notification on health service usage. While more information is needed to fill knowledge gaps in recommended action for women with dense breasts, the greatest risks to women arise from not being screened. Hence, health promotion practitio...
NF-κB transcription factors, driven by the IRAK/IKK cascade, confer treatment resistance in pancreatic ductal adenocarcinoma (PDAC), a cancer characterized by near-universal KRAS mutation. Through reverse-phase protein array and RNA sequencing we discovered that IRAK4 also contributes substantially to MAPK activation in KRAS-mutant PDAC. IRAK4 ablation completely blocked RAS-induced transformation of human and murine cells. Mechanistically, expression of mutant KRAS stimulated an inflammatory, autocrine IL-1β signaling loop that activated IRAK4 and the MAPK pathway. Downstream of IRAK4, we uncovered TPL2 (also k...
Cachexia, a devastating wasting syndrome characterized by severe weight loss with specific losses of muscle and adipose tissue, is driven by reduced food intake, increased energy expenditure, excess catabolism, and inflammation. Cachexia is associated with poor prognosis and high mortality and frequently occurs in patients with cancer, chronic kidney disease, infection, and many other illnesses. There is no effective treatment for this condition. Hypothalamic melanocortins have a potent and long-lasting inhibitory effect on feeding and anabolism, and pathophysiological processes increase melanocortin signaling tone, leadin...
More News: Alzheimer's | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | CT Scan | Funding | Hemorrhagic Stroke | Ischemic Stroke | Learning | Lung Cancer | Lung Transplant | Mammography | Medical Devices | MRI Scan | Neurology | Pathology | Prostate Cancer | Stroke | Universities & Medical Training | Venture Capital